First Patient Dosed in PRESERVE-004 Ph 2 Clinical Trial of ONC-392 + KEYTRUDA® in Patients with Platinum-Resistant Ovarian Cancer
“We are pleased to be making progress on our ONC-392 clinical program with the dosing of our first patient in the PRESERVE-004 trial in the combination arm with KEYTRUDA. We are hopeful these results will build on the promising responses we’ve seen with ONC-392 as monotherapy,” said Pan Zheng, M.D., Ph.D. Chief Medical Officer and co-founder of OncoC4. Dr. Zhang further added, “We are grateful to our partners, Merck and the GOG Foundation for their support of the PRESERVE-004 trial. We look forward to providing additional data as they become available.”
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
